References
- Fijnvandraat K, Cnossen MH, Leebeek FWG, Peters M. Diagnosis and management of haemophilia. BMJ 2012; 344: e2707. doi: 10.1136/bmj.e2707.
- Shoukat HMH, Ghulam Ghous G, Tarar ZI, Shoukat MM, Ajma N. Skewed inactivation of X chromosome: a cause of hemophilia manifestation in carrier females. Cureus 2020; 12(10):e11216. doi: 10.7759/cureus.11216.
- van Galen K, Lavin M, Skouw-Rasmussen N, et al.; European Haemophilia Consortium (EHC), European Association for Haemophilia and Allied Disorders (EAHAD). European principles of care for women and girls with inherited bleeding disorders. Haemophilia 2021; 27(5): 837-847. doi: 10.1111/hae.14379.
- Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: A meta-analystic approach using national registries. Ann Intern Med 2019; 171(8): 540-546. doi: 10.7326/M19-1208.
- Mbanya DN, Diop S, Ndoumba Mintya AN, El Kiaby M. Hemophilia care in Africa: Status and challenges. Transfus Clin Biol 2021; 28, 158-162. doi: 10.1016/j.tracli.2021.01.008.
- Stonebraker JS, Bolton-Maggs PHB, Brooker M, et al. The World Federation of Hemophilia Annual Global Survey 1999-2018. Haemophilia 2020; 26, 591-600. doi: 10.1111/hae.14012.
- Srivastava A, Santagostino E, Dougall A, et al. 2020. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1-158. doi: 10.1111/hae.14046.
- Camelo R. Ageing and increasing doses are factors related to delays for adults with haemophilia to seek prophylactic clotting factors. Am J Biomed Sci & Res 2021; 12: 451-457. doi: 10.34297/AJBSR.2021.12.001789.
- Kasirye P. Kisakye A, Nakalyango A, Barnabas A. Processes and experiences of satellite haemophilia clinic set-ups in Uganda – a short report. J Haem Pract 2022; 9(1): 76-78. doi: 10.2478/jhp-2022-0009.
- Skinner MW, Nugent D, Wilton P et al. Achieving the unimaginable: Health equity in haemophilia. Haemophilia 2020; 26: 17-24. doi: 10.1111/hae.13862.
- Kish L. Sampling organizations and groups of unequal sizes. American Sociological Review 1965; 30(4): 564-572. doi: 10.2307/2091346.
- Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med 2013; 4: 49-56. Doi: 10.2147/JBM.S43734.
- Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10. doi: 10.1111/j.1600-0609.1998.tb01103.x.
- Srivastava A. Delivery of haemophilia care in the developing world. Haemophilia 1998; 4(s2): 33-40. doi: 10.1046/j.1365-2516.1998.0040s2033.x.
- Adewuyi JO, Coutts AM, Levy L, Lloyd SE. Haemophilia care in Zimbabwe. Cent Afr J Med 1996; 42(5): 153-6.
- Ghosh K, Ghosh K. Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 2016; 32(3): 347-355. doi: 10.1007/s12288-015-0562-x.
- Verma SP. Dutta TK, Mahadevan S, et al. A randomized study of very low dose factor VIII prophylaxis in severe haemophilia — a success story from a resource limited country. Haemophilia 2016; 22(3): 342-348. doi: 10.1111/hae.12838.
- Zhou Z-Y, Riske B, Forsberg AD, et al. Self-reported barriers to hemophilia care in people with factor VIII deficiency. Am J Prev Med 2011; 41(6 Suppl 4): S346-53. doi: 10.1016/j.amepre.2011.09.003.
- Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12(11); 1935-1939. doi: 10.1111/ jth.12672.
- Babington-Ashaye A, Diop S, Geissbuhler A, de Moerloose P. Unravelling the knowledge, beliefs, behaviours and concerns of persons with haemophilia and their carriers in Senegal. Haemophilia 2020; 26(5): 840-846. doi: 10.1111/hae.14040.
- de Moerloose P. Davis JA, El Fegoun SB, Habis R, Klamroth R. Barriers and challenges for the fast treatment of bleeds in the non-haemophilia treatment centre hospital setting. Haemophilia 2020; 26(3): 422-430. doi: 10.1111/hae.13956.